Mobile

Study to evaluate 3 type of treatment (masitinib + FOLFIRI, or masitinib alone, or FOLFIRI alone) in the treatment of patients with metastatic colorectal cancer that have received 2 or 3 previous ther...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-000493-30

Study to evaluate 3 type of treatment (masitinib + FOLFIRI, or masitinib alone, or FOLFIRI alone) in the treatment of patients with metastatic colorectal cancer that have received 2 or 3 previous therapies Estudio para evaluar 3 tipos de tratamiento (masitinib + FOLFIRI, o masitinib solo, o FOLFIRI solo) en el tratamiento de pacientes con cáncer colorrectal metastásico que han recibido dos o tres terapias previas

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Overall survival (OS) Supervivencia global (SG)

Critère d'inclusion

  • Metastatic colorectal cancer after 2 or 3 previous lines of treatment,Cáncer colorrectal metastásico después de 2 o 3 líneas de tratamiento

Liens